Lurbinectedin
Showing 26 - 44 of 44
Malignant Pleural Mesothelioma, Advanced Trial in Italy, Switzerland (Lurbinectedin)
Completed
- Malignant Pleural Mesothelioma, Advanced
- Lurbinectedin
-
Alessandria, Italy
- +7 more
Jul 13, 2021
Relapsed Small Cell Lung Cancer Trial in Worldwide (Irinotecan, Lurbinectedin, Topotecan)
Recruiting
- Relapsed Small Cell Lung Cancer
- Irinotecan
- +2 more
-
Joliet, Illinois
- +94 more
Aug 12, 2022
Advanced Solid Tumors Trial in Worldwide (lurbinectedin (PM01183))
Completed
- Advanced Solid Tumors
- lurbinectedin (PM01183)
-
Santa Monica, California
- +39 more
Oct 21, 2021
Advanced Solid Tumor Trial (Lurbinectedin for injection)
Not yet recruiting
- Advanced Solid Tumor
- Lurbinectedin for injection
- (no location specified)
Nov 16, 2020
Small Cell Lung Cancer Trial (Lurbinectedin)
Approved for marketing
- Small Cell Lung Cancer
- Lurbinectedin
- (no location specified)
Jun 17, 2020
Breast Cancer, Ovarian Cancer, Gynecological Cancer Trial in New York, Madrid, Bellinzona (PM01183 + paclitaxel +/- bevacizumab)
Completed
- Breast Cancer
- +6 more
- PM01183 + paclitaxel +/- bevacizumab
-
New York, New York
- +2 more
Mar 24, 2020
Ovarian Cancer Trial in United States (Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan)
Completed
- Ovarian Cancer
- Lurbinectedin (PM01183)
- +2 more
-
Peoria, Arizona
- +27 more
Mar 25, 2020
NSCLC (NSCLC) Trial in New York (Docetaxel, Gemcitabine, Lurbinectedin (PM01183))
Completed
- Non-Small Cell Lung Cancer (NSCLC)
- Docetaxel
- +2 more
-
New York, New York(unnamed)
Sep 4, 2019
Small-cell Lung Cancer Trial in Worldwide (Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX))
Completed
- Small-cell Lung Cancer
- Lurbinectedin (PM01183)
- +4 more
-
Birmingham, Alabama
- +159 more
Sep 29, 2021
Safety of Zepzelca in Adult Extensive Stage Small Cell Lung
Recruiting
- Extensive-stage Small-cell Lung Cancer
-
Huntsville, Alabama
- +36 more
Jul 25, 2022
Solid Tumors Trial in Spain, United States (lurbinectedin (PM01183))
Completed
- Solid Tumors
- lurbinectedin (PM01183)
-
Santa Monica, California
- +15 more
Nov 6, 2019
Endometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of
Completed
- Endometrial Adenocarcinomas
- +2 more
- lurbinectedin (PM01183)
- Doxorubicin
-
Barcelona, Spain
- +6 more
Feb 24, 2020
Advanced Solid Tumors Trial in Bellinzona, London, Newcastle (lurbinectedin (PM01183), Cisplatin)
Completed
- Advanced Solid Tumors
- lurbinectedin (PM01183)
- Cisplatin
-
Bellinzona, Switzerland
- +2 more
Jan 25, 2017
Advanced Cancer, Ovarian Cancer, Endometrial Cancer Trial in Spain (PM01183 + olaparib)
Unknown status
- Advanced Cancer
- +3 more
- PM01183 + olaparib
-
Córdoba, Andalucía, Spain
- +5 more
Jun 21, 2017
Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer Trial in Brussels, Barcelona (lurbinectedin (PM01183),
Completed
- Metastatic Breast Cancer
- +2 more
- lurbinectedin (PM01183)
- capecitabine
-
Brussels, Belgium
- +1 more
Dec 13, 2016
Acute Leukemia Trial in Rochester, Houston (PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg
Completed
- Acute Leukemia
- PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
-
Rochester, Minnesota
- +1 more
Nov 4, 2015
Specific Advanced Solid Tumors Trial in Madrid, Seville, London (lurbinectedin (PM01183), Gemcitabine)
Completed
- Specific Advanced Solid Tumors
- lurbinectedin (PM01183)
- Gemcitabine
-
Madrid, Spain
- +2 more
Mar 31, 2015